Edison Investment Research Limited: Kinarus Therapeutics (KNRS): Initiation - A unique combination targeting unmet needs

London, UK, 25 August 2022

Kinarus Therapeutics (KNRS): Initiation - A unique combination targeting unmet needs

Kinarus Therapeutics is advancing KIN001, a patented orally dosed combination of p38 mitogen-activated protein kinase inhibitor pamapimod (in-licensed from Roche) and pioglitazone. Preclinical data suggest this combination may have antiviral, anti-inflammatory and anti-fibrotic activity. KIN001 is under development for the treatment of wet age-related macular degeneration (wet AMD), idiopathic pulmonary fibrosis and COVID-19. Kinarus plans to start a Phase II study in wet AMD, its lead indication, before the year end, backed by preclinical data suggesting potential benefit in reducing choroidal neovascularisation lesions. There are currently no oral drugs approved to treat wet AMD, which suggests there is a potentially significant unmet need.

Kinarus became public in Q222 through a reverse merger transaction with Perfect Holding. Given its pro forma CHF8.8m FY21 gross cash position and assuming no change in its normalised CHF5.5m FY21 free cash flow burn rate, these funds would be expected to last into mid-2023. The funding runway could be extended by Kinarus’s recent agreement to issue up to CHF20m in convertible notes to an entity manged by Yorkville. The company expects its total expenditures to be up to CHF25m to advance all three programmes through FY24.

Click here to view the full report or here to sign up to receive research as it is published.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Pooya Hemami OD CFA +44 (0)20 3077 5700 [email protected]

Soo Romanoff +44 (0)20 3077 5700 [email protected]

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        https://www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv